Iisrael - heebrea - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Iisrael - heebrea - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Iisrael - heebrea - Ministry of Health

boehringer ingelheim israel ltd. - alteplase - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - alteplase 50 mg/vial - enzymes - acute myocardial infarction in adults for the lysis of thrombi obstructing coronary arteries the improvement of ventricular function and reduction of the incidence of congestive heart failure. pulmonary embolism with hemodynamic deprivation. for fibrinolytic treatment of acute ischaemic stroke. treatment must be started within 3 hours of onset of the stroke symptoms and after prior exclusion of intracranial haemorrhage by means of appropriate imaging techniques.this treatment is restricted to a prescription by aspecialist in neurology.

Iisrael - heebrea - Ministry of Health

neopharm scientific ltd - cannabidiol drug substance ( cbd bds ); delta-9-tetrahydrocannabinol drug substance ( thc bds ) - ספריי לחלל הפה - cannabidiol drug substance ( cbd bds ) 25 mg / 1 ml; delta-9-tetrahydrocannabinol drug substance ( thc bds ) 27 mg / 1 ml - nabiximols - sativex is indicated, as add-on treatment, for symptom relief in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other medication and who demonstrate at least 20 % improvement in spasticity related symptoms during a four week trial of therapy.sativex is indicated as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis in adults.

Iisrael - heebrea - Ministry of Health

glaxo smith kline (israel) ltd - ambrisentan - טבליות מצופות פילם - ambrisentan 5 mg - ambrisentan - volibris is indicated for the treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity . efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

Iisrael - heebrea - Ministry of Health

glaxo smith kline (israel) ltd - ambrisentan - טבליות מצופות פילם - ambrisentan 10 mg - ambrisentan - volibris is indicated for the treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity . efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

Iisrael - heebrea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 100 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Iisrael - heebrea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 50 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Iisrael - heebrea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 200 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less.management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrain

Iisrael - heebrea - Ministry of Health

unipharm ltd, israel - risperidone - טבליות מצופות - risperidone 1 mg - risperidone - risperidone - risperidone is indicated for the management of schizophrania and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidone is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract